{"id":8854,"date":"2026-10-14T11:55:39","date_gmt":"2026-10-14T08:55:39","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8854"},"modified":"2026-10-14T11:55:43","modified_gmt":"2026-10-14T08:55:43","slug":"sapreme-therapeutics-spm-2551-dystrophin-restoration-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/sapreme-therapeutics-spm-2551-dystrophin-restoration-duchenne\/","title":{"rendered":"Sapreme Therapeutics, Duchenne Kas Distrofisinde SPM-2551 ile G\u00fc\u00e7l\u00fc Klinik \u00d6ncesi Distrofin Restorasyonu Bildiriyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Sapreme Therapeutics, ekzon atlama teknolojisi ve antisens oligon\u00fckleotidler (ASO&#039;lar) dahil olmak \u00fczere RNA tabanl\u0131 ila\u00e7lar kullanan, Duchenne kas distrofisi (Duchenne) i\u00e7in deneysel bir tedavi olan SPM-2551 i\u00e7in umut verici preklinik sonu\u00e7lar a\u00e7\u0131klad\u0131.<\/strong> \u015eirket, yeni bulgular\u0131 Oligon\u00fckleotid Tedavileri Derne\u011fi&#039;nin (OTS) 2026 y\u0131l\u0131ndaki 22. Y\u0131ll\u0131k Toplant\u0131s\u0131&#039;nda sundu. Sonu\u00e7lar, preklinik Duchenne modelinde tek bir d\u00fc\u015f\u00fck dozun ard\u0131ndan distrofin \u00fcretiminde \u00f6nemli art\u0131\u015flar oldu\u011funu g\u00f6sterdi.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#how-does-spm-2551-work\">SPM-2551 Nas\u0131l \u00c7al\u0131\u015f\u0131r?<\/a><\/li><li><a href=\"#dystrophin-increased-to-more-than-35-and-55-of-normal-levels\">Distrofin Normal Seviyelerin 35% ve 55% \u00dczerinde Artt\u0131<\/a><\/li><li><a href=\"#when-will-human-trials-begin\">\u0130nsan denemeleri ne zaman ba\u015flayacak?<\/a><\/li><li><a href=\"#what-do-these-results-mean-for-duchenne\">Bu sonu\u00e7lar Duchenne hastal\u0131\u011f\u0131 i\u00e7in ne anlama geliyor?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 id=\"how-does-spm-2551-work\" class=\"wp-block-heading\">SPM-2551 Nas\u0131l \u00c7al\u0131\u015f\u0131r?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi, v\u00fccudun kas g\u00fcc\u00fc ve yap\u0131s\u0131n\u0131 korumak i\u00e7in gerekli olan i\u015flevsel distrofin proteinini yeterli miktarda \u00fcretmesini engelleyen genetik de\u011fi\u015fikliklerden kaynaklan\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SPM-2551 \u00fc\u00e7 bile\u015feni bir araya getiriyor: kas dokusunu hedefleyen bir antikor, distrofin \u00fcretimini geri kazand\u0131rmaya yard\u0131mc\u0131 olmak \u00fczere tasarlanm\u0131\u015f ekson atlamal\u0131 bir antisens oligon\u00fckleotid ve Sapreme&#039;nin tescilli SPT teknolojisi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SPT teknolojisi, RNA bazl\u0131 ila\u00e7lar i\u00e7in \u00f6nemli bir zorlu\u011fu \u00e7\u00f6zmeyi ama\u00e7l\u0131yor. Bu ila\u00e7lar h\u00fccreye girdikten sonra, endozom ad\u0131 verilen k\u00fc\u00e7\u00fck yap\u0131larda hapsolabilir ve bu da hedeflerine ula\u015fmalar\u0131n\u0131 engeller. Sapreme&#039;nin teknolojisi, ilac\u0131n daha fazlas\u0131n\u0131n bu yap\u0131lardan ka\u00e7mas\u0131na ve h\u00fccre i\u00e7inde etkili olmas\u0131na yard\u0131mc\u0131 olmak \u00fczere tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<h2 id=\"dystrophin-increased-to-more-than-35-and-55-of-normal-levels\" class=\"wp-block-heading\">Distrofin Normal Seviyelerin 35% ve 55% \u00dczerinde Artt\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">En dikkat \u00e7ekici bulgular, Profes\u00f6r Annemieke Aartsma-Rus&#039;un laboratuvarlar\u0131nda geli\u015ftirilen insanla\u015ft\u0131r\u0131lm\u0131\u015f Duchenne fare modelinden elde edildi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SPM-2551, yakla\u015f\u0131k on kat daha d\u00fc\u015f\u00fck bir antisens oligon\u00fckleotid dozu kullan\u0131ld\u0131\u011f\u0131nda bile, kar\u015f\u0131la\u015ft\u0131r\u0131c\u0131 oligon\u00fckleotidlere k\u0131yasla 5-10 kat daha fazla ekson atlamas\u0131 sa\u011flad\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Distrofin sonu\u00e7lar\u0131 \u00f6zellikle cesaret vericiydi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>1 mg\/kg dozunda: Distrofin normal seviyelerin 35%&#039;sinden fazlas\u0131na ula\u015ft\u0131.<\/li>\n\n\n\n<li>3 mg\/kg dozunda: Distrofin normal seviyelerin 55%&#039;sinden fazlas\u0131na ula\u015ft\u0131.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu sonu\u00e7lar tek bir uygulamadan 56 g\u00fcn sonra \u00f6l\u00e7\u00fclm\u00fc\u015ft\u00fcr. Bulgular, daha y\u00fcksek dozlar\u0131n daha fazla distrofin restorasyonu sa\u011flad\u0131\u011f\u0131n\u0131 ve etkinin g\u00f6zlem s\u00fcresi boyunca devam etti\u011fini g\u00f6stermektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sapreme, geli\u015ftirme hedefinin distrofin seviyelerini normal seviyelerin 15%&#039;sinden daha y\u00fcksek bir seviyeye geri getirmek oldu\u011funu belirtmi\u015ftir. Bildirilen preklinik sonu\u00e7lar, test edilen her iki dozda da bu hedefi a\u015fm\u0131\u015ft\u0131r. Bununla birlikte, bu bulgular bir hayvan modelinden elde edilmi\u015ftir ve tedavinin insanlarda nas\u0131l performans g\u00f6sterece\u011fini ortaya koymamaktad\u0131r.<\/p>\n\n\n\n<h2 id=\"when-will-human-trials-begin\" class=\"wp-block-heading\">\u0130nsan denemeleri ne zaman ba\u015flayacak?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sapreme, SPM-2551 i\u00e7in 2027 y\u0131l\u0131nda IND onay\u0131 gerektiren \u00e7al\u0131\u015fmalara haz\u0131rlan\u0131yor.<\/strong> Bu \u00e7al\u0131\u015fmalar\u0131n amac\u0131, klinik denemelerin ba\u015flat\u0131lmas\u0131 i\u00e7in potansiyel bir ba\u015fvuruya destek sa\u011flayacak verileri \u00fcretmektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u015eirket, insan denemelerinin ba\u015flang\u0131\u00e7 tarihi konusunda hen\u00fcz kesin bir a\u00e7\u0131klama yapmad\u0131.<\/strong> Mevcut plan, gerekli preklinik haz\u0131rl\u0131klarla ba\u015flayarak aday\u0131 klinik geli\u015ftirme a\u015famas\u0131na do\u011fru ilerletmektir.<\/p>\n\n\n\n<h2 id=\"what-do-these-results-mean-for-duchenne\" class=\"wp-block-heading\">Bu sonu\u00e7lar Duchenne hastal\u0131\u011f\u0131 i\u00e7in ne anlama geliyor?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SPM-2551, preklinik bir modelde tek bir d\u00fc\u015f\u00fck doz uygulamas\u0131ndan sonra \u00f6nemli \u00f6l\u00e7\u00fcde distrofin restorasyonu g\u00f6stermi\u015ftir. Hedefli da\u011f\u0131t\u0131m ve endozomal ka\u00e7\u0131\u015f teknolojisi, daha d\u00fc\u015f\u00fck dozlarla ve potansiyel olarak uygulamalar aras\u0131ndaki daha uzun aral\u0131klarla etkiler elde edilmesine de yard\u0131mc\u0131 olabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bir sonraki \u00f6nemli ad\u0131m, bu sonu\u00e7lar\u0131n insanlarda g\u00fcvenli ve etkili bir \u015fekilde tekrarlan\u0131p tekrarlanamayaca\u011f\u0131n\u0131n belirlenmesi olacakt\u0131r. Klinik denemeler bu kan\u0131t\u0131 sa\u011flayana kadar, SPM-2551 deneysel bir tedavi olmaya devam edecek ve Duchenne kas distrofisi olan ki\u015filer i\u00e7in potansiyel faydalar\u0131 hen\u00fcz belirlenmemi\u015ftir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha Fazlas\u0131n\u0131 Ke\u015ffedin<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/map\/\" target=\"_blank\" rel=\"noopener\">Duchenne Klinik Ara\u015ft\u0131rma Yerleri Haritas\u0131<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Sapreme Therapeutics has announced promising preclinical results for SPM-2551, an experimental treatment for Duchenne muscular dystrophy (Duchenne) that uses exon-skipping technology and RNA-based medicines, including antisense oligonucleotides (ASOs). The company presented the new findings at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 2026. The results showed substantial increases in dystrophin production following [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":8855,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[929,77,931,930,928,932,927],"class_list":["post-8854","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-dystrophin-restoration","tag-exon-skipping","tag-oligonucleotide-therapeutics","tag-rna-therapeutics","tag-sapreme-therapeutics","tag-sirna","tag-spm-2551"],"subtitle":"Sapreme Therapeutics' SPM-2551, Duchenne modelinde distrofin seviyelerinde \u00e7arp\u0131c\u0131 bir art\u0131\u015f sa\u011flad\u0131. 1 ve 3 mg\/kg dozlar\u0131nda, seviyeler s\u0131ras\u0131yla normalin 35% ve 55% de\u011ferlerini a\u015ft\u0131. Bu ekson atlama yakla\u015f\u0131m\u0131 2027'de insan denemeleri i\u00e7in haz\u0131r olabilir mi?","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8854"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8854\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8855"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}